How to buy Affimed N-V stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Affimed N-V stock

Own Affimed N-V stock in just a few minutes.

Affimed N.V is a biotechnology business based in the US. Affimed N-V shares (AFMD) are listed on the NASDAQ and all prices are listed in US Dollars. Affimed N-V employs 137 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Affimed N-V

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AFMD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Affimed N-V share price

Use our graph to track the performance of AFMD stocks over time.

Affimed N-V shares at a glance

Information last updated 2021-03-29.
52-week range$1.50 - $8.60
50-day moving average $6.55
200-day moving average $5.31
Wall St. target price$12.41
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.72

Buy Affimed N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Affimed N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Affimed N-V financials

Revenue TTM $26.9 million
Gross profit TTM $21.4 million
Return on assets TTM -22.94%
Return on equity TTM -114.04%
Profit margin -175.03%
Book value $0.64
Market capitalisation $891.9 million

TTM: trailing 12 months

Shorting Affimed N-V shares

There are currently 6.9 million Affimed N-V shares held short by investors – that's known as Affimed N-V's "short interest". This figure is 7.1% down from 7.5 million last month.

There are a few different ways that this level of interest in shorting Affimed N-V shares can be evaluated.

Affimed N-V's "short interest ratio" (SIR)

Affimed N-V's "short interest ratio" (SIR) is the quantity of Affimed N-V shares currently shorted divided by the average quantity of Affimed N-V shares traded daily (recently around 2.0 million). Affimed N-V's SIR currently stands at 3.4. In other words for every 100,000 Affimed N-V shares traded daily on the market, roughly 3400 shares are currently held short.

However Affimed N-V's short interest can also be evaluated against the total number of Affimed N-V shares, or, against the total number of tradable Affimed N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Affimed N-V's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Affimed N-V shares in existence, roughly 60 shares are currently held short) or 0.0624% of the tradable shares (for every 100,000 tradable Affimed N-V shares, roughly 62 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Affimed N-V.

Find out more about how you can short Affimed N-V stock.

Affimed N-V share dividends

We're not expecting Affimed N-V to pay a dividend over the next 12 months.

Affimed N-V share price volatility

Over the last 12 months, Affimed N-V's shares have ranged in value from as little as $1.5 up to $8.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Affimed N-V's is 2.545. This would suggest that Affimed N-V's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Affimed N-V overview

Affimed N. V. , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site